has entered into an agreement with InCellDx, a Delaware corporation having its place of business in Menlo Park, California, pursuant to which BRLI
has purchased for $6 million ($4 million cash investment and $2 million by promissory note) shares of preferred stock and warrants representing between 20% and 25% of InCellDx, depending on dilution resulting from the exercise of outstanding options.
If you own the common stock of BRLI
and purchased your shares before June 4, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D.
If you own BRLI
shares or have any questions concerning your rights and interests with regard to this matter, please contact The Law Offices of Nicholas Koluncich III, LLC.
Our investigation concerns whether the BRLI
board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders.
has developed unique informatics and service solutions for Corizon and we will continue to work with them to increase and improve efficiency in the operations covered under this contract.
is a clinical testing laboratory offering testing, information and related services to physician offices, clinics, hospitals, employers and governmental units.
operates as a national oncology laboratory as GenPath.
We believe that this will afford Onmark GPO members a unique opportunity to take advantage of the cutting-edge solutions being offered by BRLI